News
06-24-2010, 06:40 AM
Nektar Therapeutics announced today that the first patients have been dosed in a new Phase 1 dose-escalation clinical study to evaluate NKTR-102, the company's lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers. The study is being conducted at University Hospitals Case Medical Center of the Case Comprehensive Cancer Center in Cleveland, Ohio.
More... (http://www.news-medical.net/news/20100624/Nektar-commences-dosing-in-Phase-1-study-of-NKTR-102-in-combination-with-5-FUleucovorin.aspx)
More... (http://www.news-medical.net/news/20100624/Nektar-commences-dosing-in-Phase-1-study-of-NKTR-102-in-combination-with-5-FUleucovorin.aspx)